Citigroup Issues Pessimistic Forecast for Clorox (NYSE:CLX) Stock Price

Clorox (NYSE:CLX) had its price objective reduced by stock analysts at Citigroup from $130.00 to $120.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s target price points to a potential upside of 9.15% from the stock’s current price.

A number of other analysts have also recently commented on the company. BNP Paribas Exane reduced their price target on Clorox from $118.00 to $110.00 and set an “underperform” rating for the company in a research report on Friday, October 17th. The Goldman Sachs Group cut their price objective on Clorox from $115.00 to $110.00 and set a “sell” rating for the company in a research note on Wednesday, October 1st. UBS Group set a $119.00 target price on shares of Clorox and gave the stock a “neutral” rating in a research note on Tuesday. Zacks Research cut shares of Clorox from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 28th. Finally, Barclays cut their target price on shares of Clorox from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $127.60.

Clorox Stock Performance

Shares of CLX traded up $0.80 on Tuesday, reaching $109.94. The company’s stock had a trading volume of 1,774,090 shares, compared to its average volume of 1,687,181. Clorox has a 12-month low of $107.71 and a 12-month high of $171.37. The stock has a market capitalization of $13.39 billion, a P/E ratio of 16.80, a PEG ratio of 0.92 and a beta of 0.52. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57. The stock’s 50 day simple moving average is $120.28 and its two-hundred day simple moving average is $125.61.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.07. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business had revenue of $1.43 billion for the quarter, compared to analysts’ expectations of $1.41 billion. During the same quarter last year, the company posted $1.86 EPS. The company’s revenue was down 18.9% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. Research analysts forecast that Clorox will post 7.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares of the company’s stock, valued at $6,711,475.38. The trade was a 21.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.63% of the stock is owned by insiders.

Institutional Trading of Clorox

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Total Investment Management Inc. purchased a new stake in shares of Clorox during the 2nd quarter worth $25,000. American National Bank & Trust raised its holdings in Clorox by 69.5% in the second quarter. American National Bank & Trust now owns 217 shares of the company’s stock worth $26,000 after purchasing an additional 89 shares in the last quarter. NewSquare Capital LLC lifted its position in shares of Clorox by 567.6% during the second quarter. NewSquare Capital LLC now owns 227 shares of the company’s stock valued at $27,000 after buying an additional 193 shares during the last quarter. True Wealth Design LLC boosted its holdings in shares of Clorox by 1,020.0% in the 3rd quarter. True Wealth Design LLC now owns 224 shares of the company’s stock valued at $28,000 after buying an additional 204 shares in the last quarter. Finally, Root Financial Partners LLC purchased a new position in shares of Clorox in the 3rd quarter worth approximately $29,000. Institutional investors own 78.53% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.